Introduction
metabolic disease, T2DM, fasting blood glucose, postprandial blood glucose
TYPE 2 DIABETES MELLITUS, METABOLIC DISEASE, SECONDARY, HIGH INSULIN, INSULIN SENSITIVITY
Type 2 diabetes mellitus (T2DM) is a metabolic disease characterized by a decrease in pancreatic β-cell mass and function, and represents a failure to compensate for the high insulin demand of homeostatic model assessment of insulin resistant (HOMA-IR) states (The human intestines harbor a complex community of intestinal bacteria (We proposed that FMT would alter T2DM patients’ microbial ecology and thereafter improve the blood glucose and insulin sensitivity. An FMT clinical trial for the intervention of T2DM patients with metformin, FMT alone, and FMT plus metformin was initiated. The primary outcome was the evaluation of changes in insulin sensitivity (HOMA-IR and HOMA-HBCI), postprandial blood glucose (PBG), fasting blood glucose (FBG), hemoglobin A1c (HbA1c), and BMI between baseline and after 4 weeks of intervention. The secondary outcomes were the proportion of subjects acquiring least 20% of microbiota from the donor after FMT at week 4.